[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chirag G. Patil\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":51},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100437522","phase-1-trial-of-anti-pd-1-immunotherapy-and-stereotactic-radiation-in-patients-with-recurrent-glioblastoma-100437522",false,"NCT04977375","Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma","Phase Ib\u002FII Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma","Inclusion Criteria:\n\n* Age 18 years or older\n* Confirmed histologic diagnosis of WHO Grade IV, Glioblastoma Multiforme\n* GBM recurrence or progression with planned standard of care surgical resection and repeat radiation\n* Tumor size less than 6 cm\n* ECOG performance status of 0-1\n* Adequate laboratory values\n\nExclusion Criteria:\n\n* Contraindication to additional radiation\n* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor\n* Immunodeficiency diagnosis or receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone) or any other form of immunosuppressive therapy\n* Severe hypersensitivity to pembrolizumab\n\nComplete inclusion\u002Fexclusion criteria are detailed in the protocol.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this study is to assess the safety\u002Ftolerability\u002Ffeasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related AEs and the number of patients who do not necessitate a delay in surgical resection, and to assess overall survival. The secondary objectives are to assess progression free survival, and to assess the T cell clonality, CD8 T cell activation and Tumor Infiltrating Lymphocyte (TIL) score after treatment",[27],"Glioblastoma Multiforme",[29,30,31,32,33,34,35,36,37,38],"Central Nervous System Tumor","neurosurgery","Brain tumor","spinal cord tumor","surgical resection","glioma","glioblastoma","neuropathology","maximal safe resection","CNS","RECRUITING","2026-09-18",{"date":42,"type":43},"2026-09-21","ACTUAL",{"date":45,"type":43},"2021-12-09",{"date":47,"type":20},"2028-12",{"name":49,"class":50},"Chirag G. Patil","OTHER",""]